On 4 August 2026, AIM Vaccine Co., Ltd. released its Monthly Return for Equity Issuer, confirming that no changes occurred in the company’s share structure for the month ended 31 July 2026.

• Registered share capital held steady at RMB 1.23 billion, comprising 507.67 million H shares and 718.89 million domestic shares, each with a par value of RMB 1.

• Issued share capital was unchanged: 507.67 million H shares and 718.89 million domestic shares, with no treasury shares outstanding or movements recorded.

• The company affirmed compliance with the Hong Kong Main Board’s minimum 25% public-float requirement for its H shares.

• There were no new share options, warrants, convertible instruments, or other equity-linked agreements initiated or outstanding during the period.

• AIM Vaccine’s board confirmed that all regulatory and listing rule obligations related to issued securities continue to be met.

The filing underscores a month of capital stability for AIM Vaccine, with no dilution events and a maintained free-float ratio in line with Hong Kong Stock Exchange requirements.